Insider Transactions Reported by 17 Insiders of ENANTA PHARMACEUTICALS INC

Symbol: ENTA on Nasdaq
Location: Watertown, MA

Quick Takeaways

ENTA - ENANTA PHARMACEUTICALS INC has 17 insiders with reported activity on this page.
Net insider value flow over the last year: -$183,167.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: ; sell value: $183,166.
Net share flow: -12,883.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$183,167.

Buys

Shares: 0

Insiders: 0

Sells

$183,167

Shares: 12,883

Insiders: 7

Net

-$183,167

Shares: -12,883

Insiders: -7

Window (months)	Sell shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	12,883	$0	$183,167	-$183,167
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

ENANTA PHARMACEUTICALS INC executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Ph.D. Jay R. Luly	President and CEO, Director	$12,424,161	-$67,493	-0.54%	Mixed	12 Feb 2026
Yat Sun Or	Chief Scientific Officer	$5,341,669	-$34,010	-0.63%	Mixed	12 Feb 2026
Nathaniel S. Gardiner	Chief Legal Officer	$1,003,410			Mixed	26 Feb 2024
Brendan Luu	Chief Business Officer	$593,284	-$19,837	-3.2%	Mixed	12 Feb 2026
Paul J. Mellett	Chief Fin. & Admin Officer	$535,992			Mixed	12 Feb 2025
Tara Lynn Kieffer	Chief Product Strategy Officer	$483,431	-$29,968	-5.8%	Mixed	12 Feb 2026
Rottinghaus Scott T.	Chief Medical Officer	$359,869	-$11,356	-3.1%	Mixed	12 Feb 2026
Nathalie Adda	Sr. VP & Chief Medical Officer	$319,036			Mixed	01 Apr 2022
Harry R. Trout III	Vice President, Finance (Principal Financial Officer)	$232,632	-$13,017	-5.3%	Filing P/S	05 Dec 2025
Kathleen S. Capps	Executive Director of Accounting, Controller (Principal Accounting Officer)	$119,204	-$7,486	-5.9%	Filing P/S	05 Dec 2025
Matthew Paul Kowalsky	Chief Legal Officer	$51,171			Mixed	12 Feb 2026
Lesley Russell	Director				Mixed	11 Mar 2026
Kristine Peterson	Director				Mixed	11 Mar 2026
Terry Vance	Director				Mixed	11 Mar 2026
Yujiro S. Hata	Director				Mixed	11 Mar 2026
Mark G. Foletta	Director				Mixed	11 Mar 2026
Bruce L. A. Carter	Director				Mixed	11 Mar 2026

Top shareholders of ENANTA PHARMACEUTICALS INC (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
JANUS HENDERSON GROUP PLC	13F 13D/G	Company	12% from 13D/G	3,729,659	$58,760,778	—	31 Dec 2025	13F 13D/G
BlackRock, Inc.	13F 13D/G	Company	7.8% from 13D/G	3,076,282	$48,512,966	—	31 Dec 2025	13F 13D/G
Farallon Capital Partners, L.P.	13D/G	Dapice Joshua J.	9.8%	2,816,862	$44,421,914	+$11,174,622	31 Dec 2025	13D/G
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	9.6%	2,772,262	$43,718,572	—	31 Dec 2025	13F
Krensavage Asset Management, LLC	13F	Company	9.6%	2,766,390	$43,626,000	—	31 Dec 2025	13F
VANGUARD GROUP INC	13F	Company	8%	2,301,794	$36,299,291	—	31 Dec 2025	13F
Deep Track Capital, LP	13F 13D/G	Company	6.8% from 13D/G	1,956,867	$30,859,793	—	31 Dec 2025	13F 13D/G
ACADIAN ASSET MANAGEMENT LLC	13F	Company	3.1%	885,126	$13,946,000	—	31 Dec 2025	13F
Ph.D. Jay R. Luly	3/4/5 13D/G	President and CEO, Director · Jay R. Luly, Ph.D.	7.7% from 13D/G	1,181,871 mixed-class rows	$12,424,161	-$67,493	12 Feb 2026	3/4/5 13D/G
MILLENNIUM MANAGEMENT LLC	13F	Company	2.3%	670,428	$10,572,650	—	31 Dec 2025	13F
INTEGRATED CORE STRATEGIES (US) LLC	13D/G	Millennium Management LLC	2.3%	670,428	$10,572,650	-$7,381,243	31 Dec 2025	13D/G
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	2.2%	645,791	$10,186,549	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	2.2%	642,200	$10,127,494	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	1.8%	523,715	$8,258,986	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	1.5%	438,939	$6,922,068	—	31 Dec 2025	13F
Hillsdale Investment Management Inc.	13F	Company	1.5%	422,300	$6,659,671	—	31 Dec 2025	13F
Spruce Street Capital LP	13F	Company	1.4%	389,687	$6,145,364	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	1.3%	385,276	$6,075,802	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	1.2%	339,918	$5,360,518	—	31 Dec 2025	13F
Yat Sun Or	3/4/5	Chief Scientific Officer	— mixed-class rows	484,854 mixed-class rows	$5,341,669	-$34,010	12 Feb 2026	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	0.99%	285,448	$4,501,515	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.88%	253,811	$4,002,599	—	31 Dec 2025	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.81%	234,835	$3,703,349	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.8%	229,889	$3,625,349	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.76%	218,816	$3,450,728	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.76%	218,636	$3,447,890	—	31 Dec 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.73%	211,614	$3,337,236	—	31 Dec 2025	13F
D. E. Shaw & Co., Inc.	13F	Company	0.58%	167,714	$2,644,850	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.5%	143,300	$2,259,841	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.39%	112,964	$1,781,442	—	31 Dec 2025	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.36%	103,903	$1,638,550	—	31 Dec 2025	13F
Stonepine Capital Management, LLC	13F	Company	0.35%	100,000	$1,577,000	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.35%	99,884	$1,575,171	—	31 Dec 2025	13F
SEI INVESTMENTS CO	13F	Company	0.34%	98,782	$1,557,795	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.32%	93,158	$1,469,102	—	31 Dec 2025	13F
Nuveen, LLC	13F	Company	0.3%	86,056	$1,357,103	—	31 Dec 2025	13F
Opaleye Management Inc.	13F	Company	0.26%	75,000	$1,182,750	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.25%	72,588	$1,144,712	—	31 Dec 2025	13F
PDT Partners, LLC	13F	Company	0.24%	69,197	$1,091,237	—	31 Dec 2025	13F
PANAGORA ASSET MANAGEMENT INC	13F	Company	0.23%	66,990	$1,056,432	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.23%	65,978	$1,040,473	—	31 Dec 2025	13F
Squarepoint Ops LLC	13F	Company	0.23%	65,966	$1,040,284	—	31 Dec 2025	13F
DIADEMA PARTNERS LP	13F	Company	0.23%	65,138	$1,027,226	—	31 Dec 2025	13F
Nathaniel S. Gardiner	3/4/5	Chief Legal Officer	— mixed-class rows	189,427 mixed-class rows	$1,003,410	—	26 Feb 2024	3/4/5
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.22%	63,219	$996,964	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.19%	54,989	$867,177	—	31 Dec 2025	13F
Campbell & CO Investment Adviser LLC	13F	Company	0.19%	54,149	$853,930	—	31 Dec 2025	13F
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	13F	Company	0.18%	52,728	$831,521	—	31 Dec 2025	13F
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	13F	Company	0.17%	50,434	$795,344	—	31 Dec 2025	13F
Assenagon Asset Management S.A.	13F	Company	0.16%	45,877	$723,480	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for ENANTA PHARMACEUTICALS INC

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Terry Vance	ENTA	Stock Option (right to buy)	Award				20,000	20,000	11 Mar 2026	Direct
Lesley Russell	ENTA	Stock Option (right to buy)	Award				20,000	20,000	11 Mar 2026	Direct
Kristine Peterson	ENTA	Stock Option (right to buy)	Award				20,000	20,000	11 Mar 2026	Direct
Yujiro S. Hata	ENTA	Stock Option (right to buy)	Award				20,000	20,000	11 Mar 2026	Direct
Mark G. Foletta	ENTA	Stock Option (right to buy)	Award				20,000	20,000	11 Mar 2026	Direct
Bruce L. A. Carter	ENTA	Stock Option (right to buy)	Award				20,000	20,000	11 Mar 2026	Direct
Matthew Paul Kowalsky	ENTA	Common Stock	Tax liability	-34.6%			-1,902	3,591	12 Feb 2026	Direct
Matthew Paul Kowalsky	ENTA	Common Stock	Award				5,493	5,493	12 Feb 2026	Direct
Brendan Luu	ENTA	Common Stock	Tax liability	-7.26%			-3,257	41,634	12 Feb 2026	Direct
Brendan Luu	ENTA	Common Stock	Award	17.1%			6,562	44,891	12 Feb 2026	Direct
Tara Lynn Kieffer	ENTA	Common Stock	Tax liability	-8.76%			-3,257	33,925	12 Feb 2026	Direct
Tara Lynn Kieffer	ENTA	Common Stock	Award	21.4%			6,562	37,182	12 Feb 2026	Direct
Rottinghaus Scott T.	ENTA	Common Stock	Tax liability	-11.9%			-3,413	25,254	12 Feb 2026	Direct
Rottinghaus Scott T.	ENTA	Common Stock	Award	31.6%			6,875	28,667	12 Feb 2026	Direct
Yat Sun Or	ENTA	Common Stock	Tax liability	-0.9%			-3,413	374,854	12 Feb 2026	Direct
Yat Sun Or	ENTA	Common Stock	Award	1.85%			6,875	378,267	12 Feb 2026	Direct
Jay R. Luly	ENTA	Common Stock	Tax liability	-0.7%			-6,155	871,871	12 Feb 2026	Direct
Jay R. Luly	ENTA	Common Stock	Award	2.33%			20,000	878,026	12 Feb 2026	Direct
Kathleen S. Capps	ENTA	Common Stock	Sale	-3.71%	$4,596	$14.23	-323	8,377	05 Dec 2025	Direct
Harry R. Trout III	ENTA	Common Stock	Sale	-3.21%	$7,713	$14.23	-542	16,348	05 Dec 2025	Direct
Rottinghaus Scott T.	ENTA	Common Stock	Sale	-3.53%	$11,356	$14.23	-798	21,792	05 Dec 2025	Direct
Brendan Luu	ENTA	Common Stock	Sale	-3.51%	$19,837	$14.23	-1,394	38,329	05 Dec 2025	Direct
Tara Lynn Kieffer	ENTA	Common Stock	Sale	-6.44%	$29,968	$14.23	-2,106	30,620	05 Dec 2025	Direct
Yat Sun Or	ENTA	Common Stock	Sale	-0.64%	$34,010	$14.23	-2,390	371,392	05 Dec 2025	Direct
Jay R. Luly	ENTA	Common Stock	Sale	-0.55%	$67,493	$14.23	-4,743	858,026	05 Dec 2025	Direct
Kathleen S. Capps	ENTA	Common Stock	Sale	-2.32%	$2,890	$13.96	-207	8,700	02 Dec 2025	Direct
Harry R. Trout III	ENTA	Common Stock	Sale	-2.2%	$5,305	$13.96	-380	16,890	02 Dec 2025	Direct
Kathleen S. Capps	ENTA	Common Stock	Tax liability	-0.95%			-85	8,907	01 Dec 2025	Direct
Harry R. Trout III	ENTA	Common Stock	Tax liability	-0.6%			-105	17,270	01 Dec 2025	Direct
Brendan Luu	ENTA	Common Stock	Tax liability	-1.24%			-498	39,723	01 Dec 2025	Direct
Tara Lynn Kieffer	ENTA	Common Stock	Tax liability	-2.25%			-753	32,726	01 Dec 2025	Direct
Yat Sun Or	ENTA	Common Stock	Tax liability	-0.2%			-753	373,782	01 Dec 2025	Direct
Jay R. Luly	ENTA	Common Stock	Tax liability	-0.22%			-1,885	862,769	01 Dec 2025	Direct
Kathleen S. Capps	ENTA	Common Stock	Award	54.3%			3,163	8,992	25 Nov 2025	Direct
Kathleen S. Capps	ENTA	Stock Option (right to buy)	Award				6,325	6,325	25 Nov 2025	Direct
Harry R. Trout III	ENTA	Common Stock	Award	59.2%			6,463	17,375	25 Nov 2025	Direct
Harry R. Trout III	ENTA	Stock Option (right to buy)	Award				12,925	12,925	25 Nov 2025	Direct
Brendan Luu	ENTA	Stock Option (right to buy)	Award				90,000	90,000	25 Nov 2025	Direct
Tara Lynn Kieffer	ENTA	Stock Option (right to buy)	Award				100,000	100,000	25 Nov 2025	Direct
Matthew Paul Kowalsky	ENTA	Stock Option (right to buy)	Award				90,000	90,000	25 Nov 2025	Direct
Rottinghaus Scott T.	ENTA	Stock Option (right to buy)	Award				110,000	110,000	25 Nov 2025	Direct
Yat Sun Or	ENTA	Stock Option (right to buy)	Award				110,000	110,000	25 Nov 2025	Direct
Jay R. Luly	ENTA	Stock Option (right to buy)	Award				310,000	310,000	25 Nov 2025	Direct
Rottinghaus Scott T.	ENTA	Common Stock	Tax liability	-8.94%			-2,217	22,590	08 Aug 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.